CER Daily Newsfeed

The IRA's Price Setting Doesn't Guarantee Lower Costs or Better Access

(11/17, Matthew Norawong, PhRMA) comments “...Instead of lowering out-of-pocket costs, price setting siphons billions of dollars away that could otherwise be used to research and develop new, innovative medicines. That means fewer treatments to fight against our nation’s toughest health care challenges like cancer, mental health and other chronic conditions. All while China is seeking to overtake the U.S. as the global leader in drug development––much like how they surpassed Europe just a few years ago.” Full

Accelerating JCA Readiness with an AI-Enabled Framework for Early PICO Identification

(11/18, The Evidence Base) reports “...At ISPOR Europe 2025, researchers from Certara presented new work addressing this challenge. In their poster, ‘Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments,’ Kurt Neeser, Elvira Müller, Dmitry Gultyaev, and Vishwas R Agashe from Evidence and Access at Certara introduce an integrated, evidence-based framework to systematically identify and prioritize PICO scenarios during early evidence planning and preparation for JCA submission. In this interview we speak with Kurt Neeser, Elvira Müller and Vishwas Agashe to learn more about their research and its implications for JCA preparedness.” Full

UK MHRA Could 'Evolve' Its 'Clunky' Early Access To Medicines Scheme

(11/17, Eliza Slawther, Pink Sheet) reports “...[MHRA's Julian Beach] said it was not solely the regulator’s role to facilitate access to medicines. The MHRA would need to work with the National Health Service and the health technology assessment agencies of the devolved UK nations on providing earlier access to medicines for patients, he explained.” Subscription Required